Antiperinuclear factor in chronic juvenile arthritis

SIR: Nesher et al recently described the first comprehensive series concerning antiperinuclear factor in juvenile chronic arthritis (JCA). They found an overall positivity of 34% in patients with the polyarticular type of the disease (16/28 patients were positive). Our results are at variance with these data: in a group of 313 patients, only two were positive, all of them children with polyarticular onset (table). Thus our results are more in line with a recently reported Czechoslovakian series (Barfield R, 17th Prague international pediatric rheumatology symposium, 1992). Our material consisted of 49 fresh and 264 frozen serum samples. One of the former and two of the latter were positive. As antiperinuclear factor is predominantly, if not exclusively, of the IgG class, sample preservation would seem unlikely to have influenced the results. A more plausible explanation for the discrepancy lies in the immunofluorescence system. A major confounding factor causing variability in antiperinuclear factor results is the variation in substrate sensitivity, between different donors, of the buccal cells that contain the antigen. This drawback has barred antiperinuclear factor from coming into general use despite the long history of the test. We used a recently described improved technique that includes detergent treatment of the cells, which is reported to minimise, albeit not entirely exclude, donor differences. We tested the serum samples at a standard dilution of 1:5, which is also the titre we recorded for the WHO rheumatoid factor reference preparation that has been proposed by Feltskamp et al as the reference standard for antiperinuclear factor, too. Sixty per cent of serum samples from adult patients with rheumatoid arthritis tested in parallel by this technique were positive (manuscript in preparation).

In conclusion, antiperinuclear factor seems to be a specific but insensitive marker for the JCA subset with polyarticular onset that resembles adult rheumatoid arthritis. It contributes to the evidence for a basic difference between JCA in general and adult rheumatoid arthritis. The need for a common reference standard in future studies is obvious.

ROBERT VON ESSEN
HEIKKI VILJOKI
ANNELI SAVOLAINEN
JARKO HAAPASAARI
ULLA-MAIJA OKSALA
Rheumatism Foundation of the Finnish SF–18120 Helsinki
Finland

Patients with juvenile chronic arthritis

Oncet type Antiperinuclear factor positive No of patients

Polyarticular
Rheumatoid factor positive 3/15
Rheumatoid factor negative 0/73
Oligoarticular 0/195
Systemic 0/30
Total 3/313

LETTERS TO
THE EDITOR

Antiperinuclear factor in chronic juvenile arthritis

SIR: Nesher et al recently described the first comprehensive series concerning antiperinuclear factor in juvenile chronic arthritis (JCA). They found an overall positivity of 34%; in patients with the polyarticular type of the disease 16/28 patients were positive. Our results are at variance with these data: in a group of 313 patients, only two were positive, all of them children with polyarticular onset (table). Thus our results are more in line with a recently reported Czechoslovakian series (Barfield R, 17th Prague international pediatric rheumatology symposium, 1992). Our material consisted of 49 fresh and 264 frozen serum samples. One of the former and two of the latter were positive. As antiperinuclear factor is predominantly, if not exclusively, of the IgG class, sample preservation would seem unlikely to have influenced the results. A more plausible explanation for the discrepancy lies in the immunofluorescence system. A major confounding factor causing variability in antiperinuclear factor results is the variation in substrate sensitivity, between different donors, of the buccal cells that contain the antigen. This drawback has barred antiperinuclear factor from coming into general use despite the long history of the test. We used a recently described improved technique that includes detergent treatment of the cells, which is reported to minimise, albeit not entirely exclude, donor differences. We tested the serum samples at a standard dilution of 1:5, which is also the titre we recorded for the WHO rheumatoid factor reference preparation that has been proposed by Feltskamp et al as the reference standard for antiperinuclear factor, too. Sixty per cent of serum samples from adult patients with rheumatoid arthritis tested in parallel by this technique were positive (manuscript in preparation).

In conclusion, antiperinuclear factor seems to be a specific but insensitive marker for the JCA subset with polyarticular onset that resembles adult rheumatoid arthritis. It contributes to the evidence for a basic difference between JCA in general and adult rheumatoid arthritis. The need for a common reference standard in future studies is obvious.

ROBERT VON ESSEN
HEIKKI VILJOKI
ANNELI SAVOLAINEN
JARKO HAAPASAARI
ULLA-MAIJA OKSALA
Rheumatism Foundation of the Finnish SF–18120 Helsinki
Finland

Patients with juvenile chronic arthritis

Oncet type Antiperinuclear factor positive No of patients

Polyarticular
Rheumatoid factor positive 3/15
Rheumatoid factor negative 0/73
Oligoarticular 0/195
Systemic 0/30
Total 3/313

Diagnostic role of antikeratin antibodies in RA

SIR: We read with interest the article by Paimela et al on the diagnostic and prognostic value of antikeratin antibodies in rheumatoid arthritis (RA).

We recently studied two groups with RA using indirect immunofluorescence for antibodies to the stratum corneum keratin 1 and 10. In the group of white patients with RA (n = 30) we found a seroprevalence for antikeratin antibodies of 53%. In contrast, among the African rheumatoid group (n = 54), who had significantly milder disease, no antikeratin antibody seroprevalence of 6% was seen. Our findings suggest that there may be a wide variation in the incidence of antikeratin antibodies, and even when immunofluorescence is used there is a low sensitivity, low negative predictive value, and a moderate specificity. There is also evidence that immunoabsorption of serum with heterogenous nuclear RNP core protein A1, in which the C-terminal domain shows diagnostical homology with keratin, results in a significant reduction of antikeratin antibody titres.

Our view is that although antikeratin antibodies may be useful in the absence of RA, these antibodies are of low discriminating ability when the disease is mild, as is often the case in early RA. Hence they are likely to be of little use for routine diagnostic purposes.

A O ADEBAJO
B L HAZLEMAN
Rheumatology Research Unit
Addenbrooke’s Hospital
Cambridge CB2 2QQ
United Kingdom

D G WILLIAMS
R N MAINI
Kennedy Institute of Rheumatology
Hammersmith
London W6 7DW
United Kingdom


Suflasalazine induced hepatitis in adult Still’s disease

SIR: We were interested to read the report of sulfasalazine induced hepatitis in juvenile chronic arthritis, noting that one of the two patients had the systemic onset variety.

We report an adverse reaction to sulphasalazine in a patient with adult Still’s disease and comment on a potential mechanism for enhanced drug toxicity in this disorder.

A 42 year old West Indian woman presented in November 1989 with malaise, weight loss, intermittent fever, and a symmetrical inflammatory polyarthropathy with erythema nodosum and desquamating skin rash. Investigations showed a neutrophil leucocytosis (white cell count 15·8×10⁹/L) and a marked acute phase response (C reactive protein (CRP) 126 mg/l). Extensive screen for bacterial and viral infection was negative. A skin biopsy specimen showed perivascular polymorph infiltrates compatible with a small vessel vasculitis. Carpal erosions were seen on wrist radiographs,

Downloaded from http://ard.bmj.com/ on June 22, 2017 - Published by group.bmj.com
Diagnostic role of antikeratin antibodies in RA.

A O Adebajo, B L Hazleman, D G Williams and R N Maini

*Ann Rheum Dis* 1992 51: 1264
doi: 10.1136/ard.51.11.1264-c

Updated information and services can be found at:
http://ard.bmj.com/content/51/11/1264.3.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/